---
title: "Leukemia"
order: 3
category: "Hematology"
---

# Leukemia

## Overview

Leukemia is a heterogeneous group of hematologic malignancies characterized by clonal proliferation of abnormal hematopoietic cells in the bone marrow and peripheral blood. Leukemias are classified based on the cell lineage affected (lymphoid vs. myeloid) and the clinical course (acute vs. chronic). Understanding the molecular pathogenesis, classification systems, and treatment strategies is essential for optimal management of these complex disorders.

### Classification

**By lineage and acuity**:
- **Acute lymphoblastic leukemia (ALL)**: Malignant proliferation of lymphoid progenitor cells
- **Acute myeloid leukemia (AML)**: Malignant proliferation of myeloid progenitor cells
- **Chronic lymphocytic leukemia (CLL)**: Clonal proliferation of mature B lymphocytes
- **Chronic myeloid leukemia (CML)**: Clonal proliferation of myeloid cells, characterized by Philadelphia chromosome

**Acute vs. Chronic**:
- **Acute leukemia**: Rapid onset, immature blast cells, aggressive course, requires urgent treatment
- **Chronic leukemia**: Indolent onset, mature cells, slower progression, may observe initially

### Epidemiology

**Acute lymphoblastic leukemia (ALL)**:
- Incidence: 1.7 per 100,000 persons per year
- Most common malignancy in children (25% of childhood cancers)
- Bimodal age distribution: Peak at 2-5 years, second peak in elderly
- 60% of cases in children <20 years, 40% in adults

**Acute myeloid leukemia (AML)**:
- Incidence: 4.3 per 100,000 persons per year
- Median age: 68 years (predominantly disease of elderly)
- 80% of acute leukemias in adults
- ~20,000 new cases annually in US

**Chronic lymphocytic leukemia (CLL)**:
- Incidence: 4.9 per 100,000 persons per year
- Most common leukemia in Western countries
- Median age: 70 years (rare <40 years)
- Male predominance (2:1)
- ~20,000 new cases annually in US

**Chronic myeloid leukemia (CML)**:
- Incidence: 1.8 per 100,000 persons per year
- Median age: 65 years
- 15% of adult leukemias
- ~9,000 new cases annually in US

## Pathophysiology

### Acute Lymphoblastic Leukemia

**Molecular pathogenesis**:
- Malignant transformation of lymphoid progenitor cells
- Chromosomal translocations create fusion genes:
  - **t(12;21) ETV6-RUNX1**: Most common in childhood ALL (25%), favorable prognosis
  - **t(1;19) TCF3-PBX1**: 5% of ALL, pre-B cell
  - **t(4;11) MLL-AF4**: 5-10%, infants, poor prognosis
  - **t(9;22) BCR-ABL1** (Philadelphia chromosome): 25% of adult ALL, 3% of childhood ALL, poor prognosis (improved with TKIs)
  - **Hyperdiploidy** (>50 chromosomes): Favorable prognosis in children
  - **Hypodiploidy** (<44 chromosomes): Poor prognosis
- Gene mutations: PAX5, IKZF1, CDKN2A/B alterations

**Classification**:
- **B-cell ALL**: 85% of cases
  - Early pre-B, pre-B, mature B-cell (Burkitt leukemia/lymphoma)
- **T-cell ALL**: 15% of cases
  - Associated with mediastinal mass, higher WBC, CNS involvement
  - Slightly better prognosis with modern therapy

**Immunophenotype** (flow cytometry):
- **B-ALL**: CD19, CD20, CD22, CD79a, cytoplasmic CD79a, TdT, CD10 (common ALL antigen)
- **T-ALL**: CD2, CD3 (surface or cytoplasmic), CD5, CD7, TdT

### Acute Myeloid Leukemia

**Molecular pathogenesis**:
- Clonal proliferation of myeloid progenitor cells
- Two-hit model:
  - **Class I mutations**: Proliferative advantage (FLT3, KRAS, NRAS, KIT)
  - **Class II mutations**: Impaired differentiation (RUNX1-RUNX1T1, PML-RARA, CEBPA, NPM1)

**Recurrent genetic abnormalities**:
- **t(15;17) PML-RARA**: Acute promyelocytic leukemia (APL, M3)
  - 10-15% of AML, unique biology and treatment (ATRA, arsenic trioxide)
- **t(8;21) RUNX1-RUNX1T1**: 5-10%, favorable prognosis
- **inv(16)/t(16;16) CBFB-MYH11**: 5-10%, favorable prognosis
- **Normal karyotype with NPM1 mutation and FLT3-ITD negative**: Favorable prognosis
- **FLT3-ITD mutation**: 30% of AML, poor prognosis (tyrosine kinase)
- **TP53 mutations**: Therapy-related AML, poor prognosis
- **Complex karyotype** (≥3 abnormalities): Poor prognosis

**WHO classification (2016)**:
- AML with recurrent genetic abnormalities
- AML with myelodysplasia-related changes
- Therapy-related AML
- AML, not otherwise specified (FAB classification M0-M7)

**FAB classification** (morphologic):
- M0: Minimally differentiated
- M1: Without maturation
- M2: With maturation
- M3: Acute promyelocytic leukemia (APL)
- M4: Acute myelomonocytic
- M5: Acute monocytic
- M6: Acute erythroid
- M7: Acute megakaryoblastic

**Immunophenotype**:
- CD13, CD33, CD117, MPO (myeloperoxidase), HLA-DR
- CD34 (immature)

### Chronic Lymphocytic Leukemia

**Molecular pathogenesis**:
- Clonal proliferation of mature B lymphocytes (CD5+ B cells)
- Accumulation of functionally incompetent B cells (apoptosis resistance)
- Chromosomal abnormalities:
  - **del(13q)**: Most common (50-60%), favorable prognosis
  - **Trisomy 12**: 10-20%, intermediate prognosis
  - **del(11q)**: 10-20%, ATM gene, bulky lymphadenopathy, poor prognosis
  - **del(17p)**: 5-10%, TP53 deletion, worst prognosis, resistant to chemotherapy
- **IGHV mutation status**:
  - Mutated IGHV: Favorable prognosis
  - Unmutated IGHV: Poor prognosis, aggressive disease
- Gene mutations: TP53, NOTCH1, SF3B1, BIRC3

**Immunophenotype** (flow cytometry):
- CD5, CD19, CD20 (dim), CD23, surface immunoglobulin (dim), kappa or lambda light chain restriction

**Monoclonal B-cell lymphocytosis (MBL)**:
- Precursor to CLL
- CLL phenotype with <5,000 B cells/μL
- No lymphadenopathy, organomegaly, or cytopenias
- Progresses to CLL at 1-2% per year

### Chronic Myeloid Leukemia

**Molecular pathogenesis**:
- **Philadelphia chromosome**: t(9;22) translocation (>95% of cases)
- **BCR-ABL1 fusion gene**: Creates constitutively active tyrosine kinase
  - Promotes cell proliferation, inhibits apoptosis
  - Three breakpoint regions: e13a2 or e14a2 (p210, most common), e1a2 (p190), e19a2 (p230)
- BCR-ABL1 drives clonal expansion of myeloid cells

**Phases**:
1. **Chronic phase** (85% at diagnosis):
   - Insidious onset, often asymptomatic
   - Elevated WBC with left shift (mature and immature forms)
   - <10% blasts in blood or marrow
   - Responds well to tyrosine kinase inhibitors (TKIs)

2. **Accelerated phase**:
   - 10-19% blasts in blood or marrow
   - Basophils ≥20%
   - Persistent thrombocytopenia (<100,000/μL) or thrombocytosis (>1,000,000/μL) unresponsive to therapy
   - Clonal evolution (additional cytogenetic abnormalities)
   - Increasing spleen size or WBC despite therapy

3. **Blast phase** (blast crisis):
   - ≥20% blasts in blood or marrow
   - Extramedullary blast proliferation
   - Resembles acute leukemia (70% myeloid, 30% lymphoid)
   - Poor prognosis, median survival 3-6 months

## Clinical Presentation

### Acute Leukemia (ALL and AML)

**Bone marrow failure symptoms** (from cytopenias):
- **Anemia**: Fatigue, weakness, dyspnea, pallor
- **Thrombocytopenia**: Petechiae, purpura, ecchymoses, bleeding (gums, nose, GI, intracranial)
- **Neutropenia**: Recurrent infections, fever

**Leukemic infiltration symptoms**:
- **Bone pain**: Common in ALL (periosteal infiltration)
- **Lymphadenopathy**: Cervical, axillary, inguinal nodes (more common in ALL)
- **Splenomegaly**: Left upper quadrant fullness, early satiety
- **Hepatomegaly**: Right upper quadrant fullness
- **Gingival hyperplasia**: AML, especially monocytic subtypes (M4, M5)
- **Skin lesions**: Leukemia cutis (papules, nodules)
- **CNS involvement**: Headache, nausea, vomiting, cranial nerve palsies, meningismus (more common in ALL)

**Constitutional symptoms**:
- Fever, night sweats, weight loss, fatigue

**B symptoms**: Fever, night sweats, weight loss >10% body weight in 6 months

**Acute promyelocytic leukemia (APL) specific**:
- **Disseminated intravascular coagulation (DIC)**: Life-threatening bleeding
- Promyelocytic granules release procoagulants
- Urgent treatment required

**Hyperleukocytosis** (WBC >100,000/μL):
- Leukostasis: Vascular occlusion by blast cells
- Respiratory distress, hypoxemia (pulmonary leukostasis)
- Altered mental status, headache, visual changes (CNS leukostasis)
- Medical emergency, requires urgent cytoreduction (leukapheresis, chemotherapy)

**Tumor lysis syndrome**:
- Hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, acute kidney injury
- Occurs after chemotherapy initiation (rapid cell lysis)

### Chronic Lymphocytic Leukemia

**Asymptomatic** (50-80% at diagnosis):
- Discovered incidentally on routine CBC (lymphocytosis)

**Symptomatic**:
- **Lymphadenopathy**: Painless, non-tender, mobile lymph nodes
- **Splenomegaly**: Abdominal fullness, early satiety (50%)
- **Hepatomegaly**: Less common (25%)
- **B symptoms**: Fever, night sweats, weight loss (advanced disease)
- **Fatigue**: Anemia (bone marrow infiltration, autoimmune hemolysis)
- **Infections**: Hypogammaglobulinemia, T-cell dysfunction
  - Recurrent sinopulmonary infections, herpes zoster

**Autoimmune complications**:
- **Autoimmune hemolytic anemia (AIHA)**: 10-25%
- **Immune thrombocytopenic purpura (ITP)**: 2-5%
- **Pure red cell aplasia**: Rare

**Richter transformation** (5-10%):
- Transformation to aggressive diffuse large B-cell lymphoma (DLBCL)
- Rapid lymph node enlargement, B symptoms, elevated LDH
- Poor prognosis

### Chronic Myeloid Leukemia

**Chronic phase**:
- **Asymptomatic** (40-50% at diagnosis): Incidental finding on CBC
- **Symptomatic**:
  - Fatigue, malaise, weight loss
  - Splenomegaly: Abdominal fullness, early satiety, left upper quadrant pain
  - Hepatomegaly (less common)
  - Hypermetabolic symptoms: Night sweats, low-grade fever
  - Bleeding, thrombosis (platelet dysfunction despite elevated count)

**Accelerated phase**:
- Progressive symptoms
- Increasing spleen size
- Fever, bone pain
- Worsening cytopenias or leukocytosis

**Blast phase**:
- Resembles acute leukemia
- Severe constitutional symptoms
- Bone pain, infections, bleeding

### Physical Examination

**General**:
- Pallor, petechiae, purpura, ecchymoses
- Fever (infection or leukemia-related)
- Cachexia (advanced disease)

**Lymph nodes**:
- Generalized lymphadenopathy (ALL, CLL)
- Nodes typically painless, non-tender, mobile

**Abdominal examination**:
- Splenomegaly: Most common in CML (90%), also ALL, AML, CLL
- Hepatomegaly: Leukemic infiltration

**Oral examination**:
- Gingival hyperplasia (monocytic AML)
- Oral petechiae, bleeding

**Skin**:
- Leukemia cutis: Papules, nodules, plaques

**Neurologic examination**:
- Cranial nerve palsies (CNS leukemia)
- Altered mental status (leukostasis, CNS involvement)

## Diagnosis

### Initial Evaluation

**Complete blood count (CBC) with differential**:
- Anemia, thrombocytopenia, neutropenia (bone marrow failure)
- **Acute leukemia**: Blasts in peripheral blood (may be low, normal, or high WBC)
- **CLL**: Absolute lymphocytosis >5,000/μL (monoclonal B cells)
- **CML**: Marked leukocytosis (often >100,000/μL) with left shift (all stages of myeloid maturation)

**Peripheral blood smear**:
- **Acute leukemia**: Blasts with high nuclear-to-cytoplasmic ratio, prominent nucleoli, Auer rods (AML)
- **CLL**: Mature lymphocytes, smudge cells (fragile lymphocytes)
- **CML**: Myeloid left shift (myeloblasts, promyelocytes, myelocytes, metamyelocytes, bands, neutrophils), basophilia, eosinophilia

**Chemistry**:
- Uric acid (tumor lysis risk)
- LDH (elevated in leukemia)
- Electrolytes, calcium, phosphate (tumor lysis syndrome)
- Creatinine, BUN (renal function)
- Liver function tests

**Coagulation studies**:
- PT, aPTT, fibrinogen, D-dimer (DIC in APL)

### Bone Marrow Examination

**Bone marrow aspiration and biopsy**:
- **Cellularity**: Hypercellular in acute leukemia
- **Blast percentage**: ≥20% defines acute leukemia (WHO)
- **Morphology**: Cell lineage identification
- **Iron stains**: Ringed sideroblasts (exclude MDS)

**Flow cytometry** (immunophenotyping):
- Determines cell lineage (B-lymphoid, T-lymphoid, myeloid)
- Essential for ALL and AML classification

**Cytogenetics** (karyotype):
- **Acute leukemia**: Identifies prognostic translocations (t(15;17), t(8;21), inv(16), t(9;22))
- **CLL**: FISH for del(13q), del(11q), del(17p), trisomy 12
- **CML**: Philadelphia chromosome t(9;22)

**Molecular studies**:
- **FISH**: Detects specific translocations
- **PCR**: Detects fusion genes (BCR-ABL1, PML-RARA)
- **Next-generation sequencing (NGS)**: Identifies gene mutations (NPM1, FLT3, TP53, CEBPA)

### Acute Lymphoblastic Leukemia

**Diagnostic criteria**:
- ≥20% lymphoblasts in bone marrow or peripheral blood

**Immunophenotype**:
- **B-ALL**: CD19, CD22, CD79a, TdT, CD10
- **T-ALL**: CD2, CD3, CD5, CD7, TdT

**Risk stratification**:
- Age: Children 1-9 years favorable, infants and adults poor
- WBC: <50,000/μL favorable, >50,000/μL poor
- Cytogenetics: Hyperdiploidy favorable, hypodiploidy poor
- **Philadelphia chromosome**: t(9;22) poor prognosis (improved with TKIs)
- CNS involvement: Poor prognosis
- **Minimal residual disease (MRD)**: Post-induction predictor of relapse

**Lumbar puncture**:
- Evaluate for CNS involvement (traumatic LP avoided)
- CNS prophylaxis indicated

### Acute Myeloid Leukemia

**Diagnostic criteria**:
- ≥20% myeloblasts in bone marrow or peripheral blood
- Exception: t(15;17), t(8;21), inv(16) define AML regardless of blast percentage

**Immunophenotype**:
- CD13, CD33, CD117, MPO, HLA-DR

**Risk stratification** (ELN 2017):
- **Favorable**:
  - t(8;21), inv(16)/t(16;16)
  - NPM1 mutation with FLT3-ITD low or negative, wild-type CEBPA
  - Biallelic CEBPA mutation
- **Intermediate**:
  - Normal karyotype not falling into favorable/adverse
  - t(9;11)
- **Adverse**:
  - Complex karyotype (≥3 abnormalities)
  - Monosomal karyotype
  - inv(3)/t(3;3), t(6;9), t(9;22)
  - -5, del(5q), -7, del(7q), -17/abn(17p)
  - TP53 mutation

**Acute promyelocytic leukemia (APL)**:
- t(15;17) PML-RARA
- DIC at presentation (fibrinogen <100 mg/dL, prolonged PT/aPTT, elevated D-dimer)
- Auer rods (faggot cells)
- Urgent treatment with ATRA + arsenic trioxide

### Chronic Lymphocytic Leukemia

**Diagnostic criteria** (International Workshop on CLL):
- Clonal B lymphocytes ≥5,000/μL in peripheral blood for ≥3 months
- Immunophenotype: CD5+, CD19+, CD20+ (dim), CD23+, surface Ig (dim)
- Monoclonal light chain restriction (kappa or lambda)

**Staging**:

**Rai staging** (US):
- **Stage 0**: Lymphocytosis only (low risk)
- **Stage I**: Lymphocytosis + lymphadenopathy (intermediate risk)
- **Stage II**: Lymphocytosis + splenomegaly or hepatomegaly (intermediate risk)
- **Stage III**: Lymphocytosis + anemia (Hgb <11 g/dL) (high risk)
- **Stage IV**: Lymphocytosis + thrombocytopenia (<100,000/μL) (high risk)

**Binet staging** (Europe):
- **Stage A**: <3 lymphoid areas involved (low risk)
- **Stage B**: ≥3 lymphoid areas involved (intermediate risk)
- **Stage C**: Anemia (Hgb <10 g/dL) or thrombocytopenia (<100,000/μL) (high risk)

**Prognostic markers**:
- **FISH**: del(17p) and del(11q) poor prognosis, del(13q) favorable
- **IGHV mutation status**: Mutated favorable, unmutated poor
- **TP53 mutation**: Poor prognosis, resistant to chemotherapy
- **β2-microglobulin**: Elevated poor prognosis
- **CD38, ZAP-70**: Surrogates for IGHV status

### Chronic Myeloid Leukemia

**Diagnostic criteria**:
- Philadelphia chromosome t(9;22) or BCR-ABL1 fusion gene
- Elevated WBC with myeloid left shift
- Basophilia, eosinophilia
- Splenomegaly

**Quantitative PCR**:
- BCR-ABL1 transcript level (baseline and monitoring)
- Expressed as International Scale (IS)

**Phase determination**:
- **Chronic phase**: <10% blasts, baseline features
- **Accelerated phase**: 10-19% blasts, or other criteria (basophils ≥20%, thrombocytopenia, clonal evolution)
- **Blast phase**: ≥20% blasts

**Risk stratification**:
- **Sokal score**: Age, spleen size, platelet count, blast percentage
- **Hasford (Euro) score**: Age, spleen size, platelet count, blast percentage, eosinophils, basophils
- **EUTOS score**: Basophils, spleen size

## Treatment

### Acute Lymphoblastic Leukemia

**Treatment phases**:

**1. Induction chemotherapy** (4-6 weeks):
- Goal: Achieve complete remission (CR)
- **Regimen**: Multi-agent chemotherapy
  - Vincristine, daunorubicin (or doxorubicin), L-asparaginase, corticosteroids (prednisone or dexamethasone)
  - ± Cyclophosphamide
- **Philadelphia chromosome-positive ALL**: Add tyrosine kinase inhibitor (imatinib, dasatinib, ponatinib)
- **CR rate**: 80-90% in children, 70-85% in adults

**2. Consolidation (intensification) chemotherapy** (several months):
- Goal: Eliminate residual disease
- High-dose methotrexate, cytarabine, L-asparaginase
- Repeat induction-type regimens

**3. CNS prophylaxis**:
- Intrathecal chemotherapy (methotrexate, cytarabine, hydrocortisone)
- High-dose systemic methotrexate
- Cranial irradiation (selected high-risk patients)

**4. Maintenance therapy** (2-3 years):
- Goal: Prevent relapse
- Daily oral mercaptopurine + weekly oral methotrexate
- Monthly vincristine + corticosteroids (pulses)
- Maintenance unique to ALL (not used in AML)

**Hematopoietic stem cell transplantation (HSCT)**:
- **Allogeneic HSCT**: High-risk ALL in first remission, relapsed disease
  - Indications: Philadelphia chromosome, hypodiploidy, persistent MRD, relapse
- **Autologous HSCT**: Not standard

**Relapsed/refractory ALL**:
- Salvage chemotherapy regimens
- Allogeneic HSCT if CR achieved
- **CAR T-cell therapy**: Tisagenlecleucel, brexucabtagene autoleucel (CD19-directed)
- **Blinatumomab**: BiTE antibody (CD3-CD19)
- **Inotuzumab ozogamicin**: Anti-CD22 antibody-drug conjugate

### Acute Myeloid Leukemia

**Treatment phases**:

**1. Induction chemotherapy**:
- Goal: Achieve complete remission
- **"7+3" regimen**: Standard induction
  - Cytarabine 100-200 mg/m² continuous infusion days 1-7
  - Daunorubicin 60-90 mg/m² or idarubicin 12 mg/m² days 1-3
- **CR rate**: 60-80% in younger patients (<60 years), 40-60% in older patients
- Bone marrow assessment day 14-21 to assess response

**2. Consolidation chemotherapy**:
- Goal: Eliminate residual disease, prevent relapse
- **High-dose cytarabine (HiDAC)**: 3 g/m² every 12 hours days 1, 3, 5 (3-4 cycles)
  - Standard for favorable/intermediate-risk AML
- Allogeneic HSCT for high-risk disease

**Acute promyelocytic leukemia (APL)**:
- **All-trans retinoic acid (ATRA)**: 45 mg/m²/day
  - Induces differentiation of promyelocytes
- **Arsenic trioxide (ATO)**: Induces apoptosis
- **Regimen**: ATRA + ATO (low-risk), ATRA + ATO + chemotherapy (high-risk)
- **Differentiation syndrome**: Fever, dyspnea, pulmonary infiltrates, weight gain
  - Treatment: Dexamethasone 10 mg IV BID
- **CR rate**: >90%, cure rate 80-90%

**Older/unfit patients**:
- **Hypomethylating agents**: Azacitidine, decitabine
- **Venetoclax**: BCL-2 inhibitor (combination with HMA or low-dose cytarabine)
- **Supportive care**: If not candidate for intensive therapy

**Targeted therapies**:
- **FLT3 inhibitors**: Midostaurin (with induction), gilteritinib (relapsed)
- **IDH1/2 inhibitors**: Ivosidenib (IDH1), enasidenib (IDH2)
- **Gemtuzumab ozogamicin**: Anti-CD33 antibody-drug conjugate

**Hematopoietic stem cell transplantation**:
- **Allogeneic HSCT**: Intermediate-risk and high-risk AML in first CR
- **Autologous HSCT**: Less common, favorable-risk AML

**Relapsed/refractory AML**:
- Salvage chemotherapy (HiDAC-based, FLAG-Ida)
- Clinical trials
- Allogeneic HSCT if CR achieved

### Chronic Lymphocytic Leukemia

**Watch and wait** (asymptomatic early-stage):
- No treatment until symptomatic or progressive disease
- Regular monitoring (CBC, physical exam every 3-6 months)

**Indications for treatment**:
- Progressive bone marrow failure (worsening cytopenias)
- Massive or progressive lymphadenopathy or splenomegaly
- Constitutional symptoms (fever, night sweats, weight loss)
- Autoimmune cytopenias refractory to steroids
- Lymphocyte doubling time <6 months

**First-line therapy**:

**Fit patients (no del(17p)/TP53 mutation)**:
- **FCR regimen**: Fludarabine, cyclophosphamide, rituximab
  - High CR rate, long remissions
  - Preferred for mutated IGHV
- **BR regimen**: Bendamustine, rituximab
  - Alternative to FCR (less toxic)

**Unfit patients or elderly**:
- **Ibrutinib**: BTK inhibitor (oral, continuous)
  - Very effective, well-tolerated
  - Can be used in all settings (first-line, relapsed, del(17p))
- **Acalabrutinib**: BTK inhibitor (fewer cardiac side effects than ibrutinib)
- **Venetoclax + obinutuzumab**: BCL-2 inhibitor + anti-CD20 antibody
  - Fixed-duration therapy (12 months)
  - High rates of undetectable MRD

**Del(17p)/TP53 mutation**:
- **Ibrutinib** or **acalabrutinib**: First-line
- **Venetoclax + obinutuzumab**: Alternative
- Chemotherapy ineffective

**Relapsed/refractory CLL**:
- Ibrutinib, acalabrutinib, venetoclax (if not used first-line)
- **Idelalisib**: PI3K inhibitor (with rituximab)
- **Zanubrutinib**: Newer BTK inhibitor
- Allogeneic HSCT (selected young patients with high-risk disease)

**Autoimmune complications**:
- AIHA: Corticosteroids, rituximab
- ITP: Corticosteroids, IVIG, rituximab

### Chronic Myeloid Leukemia

**Chronic phase**:

**Tyrosine kinase inhibitors (TKIs)** (first-line):
- **Imatinib**: 400 mg daily (first-generation TKI)
- **Dasatinib**: 100 mg daily (second-generation TKI)
- **Nilotinib**: 300 mg BID (second-generation TKI)
- **Bosutinib**: 400 mg daily (second-generation TKI)
- **Ponatinib**: 45 mg daily (third-generation TKI, T315I mutation)

**Response criteria**:
- **Hematologic response**: Normalization of CBC, no immature cells
- **Cytogenetic response**:
  - Complete (CCyR): 0% Philadelphia chromosome-positive cells
  - Partial (PCyR): 1-35% Philadelphia chromosome-positive cells
- **Molecular response**:
  - Major (MMR): BCR-ABL1 ≤0.1% IS
  - Deep (MR4.5): BCR-ABL1 ≤0.0032% IS

**Monitoring**:
- Quantitative PCR for BCR-ABL1 every 3 months
- Bone marrow cytogenetics at 3, 6, 12 months (if not CCyR by PCR)

**Treatment failure/resistance**:
- Switch to alternative TKI (second-generation or ponatinib)
- BCR-ABL1 kinase domain mutation testing (guides TKI selection)
- Consider allogeneic HSCT (young patients with treatment failure)

**Treatment-free remission (TFR)**:
- Sustained deep molecular response (MR4.5 for ≥2 years) on TKI
- Discontinue TKI, monitor closely
- ~50% remain in remission off therapy
- Restart TKI if loss of MMR

**Accelerated phase/blast phase**:
- TKI + chemotherapy
- Allogeneic HSCT (only curative option)

**Supportive care**:
- Hydroxyurea: Cytoreduction before TKI initiation (if very high WBC)
- Allopurinol: Tumor lysis prophylaxis

### Supportive Care (All Leukemias)

**Transfusion support**:
- PRBCs: Hgb <7 g/dL or symptomatic
- Platelets: <10,000/μL (prophylactic), <50,000/μL if bleeding or procedure

**Infection prophylaxis/treatment**:
- Antibacterial: Fluoroquinolone prophylaxis during neutropenia
- Antifungal: Fluconazole or posaconazole prophylaxis
- Antiviral: Acyclovir (HSV prophylaxis), CMV monitoring
- G-CSF: If prolonged neutropenia

**Tumor lysis syndrome prophylaxis**:
- Hydration: IV fluids 2-3 L/day
- Allopurinol: 300-600 mg daily (xanthine oxidase inhibitor)
- Rasburicase: Recombinant urate oxidase (if high risk)
- Avoid potassium, phosphate in IV fluids
- Monitor electrolytes, uric acid, LDH, creatinine

**Hyperleukocytosis management**:
- Hydroxyurea: Rapid cytoreduction
- Leukapheresis: If symptomatic leukostasis
- Avoid transfusion (increases viscosity) unless severe anemia

## Complications

### Acute Leukemia

- **Tumor lysis syndrome**: Hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, AKI
- **Infection**: Neutropenic fever, bacterial sepsis, invasive fungal infections
- **Bleeding**: Thrombocytopenia, DIC (especially APL)
- **Differentiation syndrome**: APL with ATRA/ATO (pulmonary infiltrates, hypoxemia)
- **Relapse**: Most common cause of treatment failure
- **Treatment-related toxicity**: Cardiotoxicity (anthracyclines), neurotoxicity (vincristine), hepatotoxicity (L-asparaginase)
- **Secondary malignancies**: Therapy-related MDS/AML

### Chronic Lymphocytic Leukemia

- **Infections**: Hypogammaglobulinemia, T-cell dysfunction
- **Autoimmune cytopenias**: AIHA, ITP, pure red cell aplasia
- **Richter transformation**: Transformation to DLBCL (5-10%), poor prognosis
- **Secondary malignancies**: Increased risk of skin cancers, solid tumors
- **Treatment-related**: Cytopenias, infections (BTK inhibitors, venetoclax)

### Chronic Myeloid Leukemia

- **Blast phase transformation**: Poor prognosis despite TKI
- **TKI side effects**:
  - Imatinib: Fluid retention, nausea, myalgias
  - Dasatinib: Pleural effusions, pulmonary arterial hypertension
  - Nilotinib: Hyperglycemia, cardiovascular events
  - Ponatinib: Arterial thrombotic events, pancreatitis

## Prognosis

### Acute Lymphoblastic Leukemia

**Children**:
- Overall 5-year survival: 85-90%
- Favorable risk: >90%
- High risk: 60-70%

**Adults**:
- Overall 5-year survival: 30-40%
- Philadelphia chromosome-positive: 30-50% with TKI + chemotherapy

**Relapsed ALL**: Poor prognosis, 5-year survival 20-30%

### Acute Myeloid Leukemia

**Overall 5-year survival**: 25-30%
- Age-dependent: <60 years: 40-45%, >60 years: 10-15%

**Risk-stratified**:
- Favorable: 60-70% (t(8;21), inv(16), NPM1+/FLT3-ITD-)
- Intermediate: 40-50%
- Adverse: 10-20% (complex karyotype, TP53 mutation)

**APL**: 80-90% cure rate with ATRA + ATO

**Relapsed AML**: Poor prognosis, 5-year survival <10%

### Chronic Lymphocytic Leukemia

**Overall median survival**: 10 years
- Stage-dependent:
  - Low risk (Rai 0, Binet A): Median survival 10-20 years
  - Intermediate risk (Rai I-II, Binet B): Median survival 7-10 years
  - High risk (Rai III-IV, Binet C): Median survival 2-4 years

**Prognostic factors**:
- Del(17p)/TP53 mutation: Median survival 2-3 years (improved with ibrutinib, venetoclax)
- Unmutated IGHV: Median survival 8 years
- Mutated IGHV: Median survival 25 years

### Chronic Myeloid Leukemia

**Chronic phase with TKI therapy**:
- 10-year survival: 80-90%
- Near-normal life expectancy if optimal response to TKI

**Accelerated phase**: Median survival 1-2 years

**Blast phase**: Median survival 3-6 months

## Key Points

- Acute leukemias require urgent treatment; chronic leukemias are often asymptomatic at diagnosis and may be observed initially
- ALL is most common in children (peak 2-5 years); AML is disease of elderly (median age 68 years)
- Acute leukemia diagnosis requires ≥20% blasts in bone marrow or blood; immunophenotyping, cytogenetics, and molecular studies are essential for classification
- ALL treatment includes induction, consolidation, CNS prophylaxis, and maintenance (2-3 years); cure rate 85-90% in children, 30-40% in adults
- AML treatment is "7+3" induction followed by consolidation with high-dose cytarabine or allogeneic HSCT; APL is treated with ATRA + arsenic trioxide (80-90% cure)
- CLL is most common leukemia in Western countries; staging by Rai (US) or Binet (Europe); del(17p)/TP53 mutation confers poor prognosis
- CLL treatment reserved for symptomatic/progressive disease; first-line options include ibrutinib (BTK inhibitor) or venetoclax + obinutuzumab (BCL-2 inhibitor)
- CML is characterized by Philadelphia chromosome t(9;22) BCR-ABL1; treated with tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib); 10-year survival 80-90%

## References

1. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373(16):1541-1552.

2. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136-1152.

3. Döhner H, Estey E, Grimwade D, et al. Diagnosis and Management of AML in Adults: 2017 ELN Recommendations from an International Expert Panel. Blood. 2017;129(4):424-447.

4. Sanz MA, Fenaux P, Tallman MS, et al. Management of Acute Promyelocytic Leukemia: Updated Recommendations from an Expert Panel of the European LeukemiaNet. Blood. 2019;133(15):1630-1643.

5. Hallek M, Cheson BD, Catovsky D, et al. iwCLL Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of CLL. Blood. 2018;131(25):2745-2760.

6. Wierda WG, Byrd JC, O'Brien S. Chronic Lymphocytic Leukemia. In: Hoffman R, Benz EJ Jr, Silberstein LE, et al., eds. Hematology: Basic Principles and Practice. 7th ed. Elsevier; 2018:1278-1294.

7. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia. Leukemia. 2020;34(4):966-984.

8. Jabbour E, Kantarjian H. Chronic Myeloid Leukemia: 2020 Update on Diagnosis, Therapy and Monitoring. Am J Hematol. 2020;95(6):691-709.

9. Terwilliger T, Abdul-Hay M. Acute Lymphoblastic Leukemia: A Comprehensive Review and 2017 Update. Blood Cancer J. 2017;7(6):e577.

10. Arber DA, Orazi A, Hasserjian R, et al. The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia. Blood. 2016;127(20):2391-2405.
